EUTOS Score (CML Prognosis on Imatinib)
EUTOS score (Hasford 2011): peripheral-blood basophils and spleen size predict 18-month complete cytogenetic response in chronic-phase CML on imatinib; > 87 marks high risk.
Open the calculator → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.
Example
- Basophils
- 8
- Spleen size
- 12
Result: EUTOS 104 — high risk (> 87): lower 18-month complete-cytogenetic-response and progression-free-survival rates.
The tool opens with these values already filled in. Replace them with your own.
What the result means
- Bands
- > 87 high risk, ≤ 87 low risk, for the 18-month complete cytogenetic response and progression-free survival on front-line imatinib. A risk stratifier, not a treatment order.
What you enter
- Basophils (% of peripheral blood)
- Spleen size (cm below costal margin; 0 if not palpable)
How this is calculated
- Formula
- EUTOS = 7 × basophils (% of peripheral blood at baseline) + 4 × spleen size (cm below the costal margin, 0 if not palpable).
Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686-692. Read the source ↗
A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.